Asset Details
Do you wish to reserve the book?
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Do you wish to request the book?
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
2016
Overview
The dose-dense delivery of chemotherapy (greater frequency of drug delivery) was explored in women with advanced ovarian cancer. All patients received carboplatin; half received paclitaxel weekly and half every 3 weeks. There were no between-group differences in progression-free survival.
Ovarian cancer, the most lethal gynecologic cancer, is responsible for approximately 14,000 deaths in the United States annually.
1
The incorporation of bevacizumab, a monoclonal antibody against vascular endothelial growth factor, in the treatment regimen prolongs progression-free survival but not overall survival.
2
–
5
A dose-dense regimen of paclitaxel involving greater frequency of drug delivery may enhance its antineoplastic effect by eliciting antiangiogenic and proapoptotic properties.
6
–
9
Weekly paclitaxel therapy prolonged survival among patients with early-stage breast cancer and those with metastatic breast cancer.
10
,
11
In a study involving patients with ovarian cancer, Japanese investigators found that dose-dense weekly paclitaxel prolonged progression-free . . .
Publisher
Massachusetts Medical Society
Subject
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Bevacizumab - administration & dosage
/ Carboplatin - administration & dosage
/ Drug Administration Schedule
/ Female
/ Humans
/ Ovarian Neoplasms - drug therapy
/ Paclitaxel - administration & dosage
/ Patients
/ Survival
